Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Natco Pharma Ltd, founded in the year 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets. Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. It is not the top stock in the pharmaceutical sector. However, Natco Pharma maintains a robust market position. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 4,126.90 | 2,811.70 | 2,043.80 | 2,155.70 | 2,022.40 |
Total Expenses | 2,453.40 | 1,949.80 | 1,841.60 | 1,576.10 | 1,453.70 |
Profit Before Tax | 1,673.50 | 861.90 | 202.20 | 579.60 | 568.70 |
Profit After Tax | 1,388.30 | 715.30 | 170 | 442.40 | 458.10 |
Operating Profit after Depreciation | 1,692.70 | 876.40 | 219.90 | 592.90 | 590.20 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 2,490.80 | 2,426.90 | 2,311.80 | 2,023.20 | 1,584.40 |
Total Non Current Assets | 2,882.80 | 2,657.10 | 2,622.40 | 2,447.10 | 2,262.20 |
Total Current Assets | 4,023.50 | 3,000.30 | 2,486.70 | 2,344.80 | 2,325.60 |
TOTAL ASSETS | 6,906.30 | 5,657.40 | 5,109.10 | 4,791.90 | 4,587.80 |
Total Shareholder's Fund | 5,853.10 | 4,873.80 | 4,263.60 | 4,121.60 | 3,773.50 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 1,211.60 | 849.10 | 46.50 | 298.80 | 417.30 |
Net Cash used in Investing Activities | -1,026.20 | -465.30 | 4 | -107.10 | -175 |
Net Cash used in Financing Activities | -246.90 | -363 | 34.80 | -185.70 | -250.80 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 3,673.60 | 2,436.50 | 1,862.40 | 1,754.60 | 1,914 |
Total Expenses | 2,118.30 | 1,665.80 | 1,706.50 | 1,362.40 | 1,330.90 |
Profit Before Tax | 1,555.30 | 770.70 | 155.90 | 392.20 | 583.10 |
Profit After Tax | 1,306.60 | 637.10 | 139.10 | 309.50 | 474.50 |
Operating Profit after Depreciation | 1,569.80 | 779.30 | 169.20 | 403.50 | 603.70 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 2,286.70 | 2,233.80 | 2,174.20 | 2,005.90 | 1,574.50 |
Total Non Current Assets | 3,143.60 | 2,893.20 | 2,810.30 | 2,584 | 2,406.80 |
Total Current Assets | 3,410.40 | 2,494.70 | 2,167.70 | 2,168.50 | 2,239.90 |
TOTAL ASSETS | 6,554 | 5,387.90 | 4,978 | 4,752.50 | 4,646.70 |
Total Shareholder's Fund | 5,592.30 | 4,702 | 4,191.90 | 4,091.10 | 3,869.50 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 1,196.40 | 784.40 | 57.70 | 183.50 | 422.50 |
Net Cash used in Investing Activities | -960.50 | -436.60 | -92.50 | -3.20 | -165 |
Net Cash used in Financing Activities | -237.30 | -346.80 | 35.60 | -183.10 | -261.10 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 1,371.10 | 1,362.60 | 1,068.30 | 758.60 | 1,031.40 |
Total Expenses | 566.80 | 557.80 | 571 | 490.50 | 573.40 |
Profit Before Tax | 818.20 | 803.60 | 477.60 | 256.30 | 439.60 |
Profit After Tax | 676.50 | 668.50 | 386.30 | 212.70 | 369 |
Operating Profit after Depreciation | 868.10 | 852.90 | 539.30 | 305.10 | 487.40 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 1,292.60 | 1,236.90 | 964.80 | 625.30 | 930.50 |
Total Expenses | 501.90 | 473.90 | 512.10 | 387 | 488.20 |
Profit Before Tax | 796.90 | 758 | 432.50 | 223.60 | 424 |
Profit After Tax | 661.10 | 636.30 | 349.10 | 192 | 360.20 |
Operating Profit after Depreciation | 842.10 | 802.80 | 488.60 | 267.80 | 467 |
₹1.5/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Natco Pharma Ltd | ₹1,243.35 | ₹22,269.63 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
19 Dec 2024, 01:05 pm
03 Dec 2024, 01:06 pm
28 Nov 2024, 11:31 am
21 Nov 2024, 05:35 pm
21 Nov 2024, 03:00 pm
View More